Disseminated Intravascular Coagulation (DIC)

Core Idea

DIC is widespread intravascular fibrin deposition causing simultaneous thrombosis and consumption coagulopathy. Tissue factor release (sepsis, trauma, malignancy) triggers thrombin generation, platelet depletion, and fibrinogen consumption, culminating in bleeding and multi-organ failure.

How It's Best Learned

Study laboratory findings: low platelet count, low fibrinogen, elevated PT/aPTT, elevated D-dimer, schistocytes on smear. Understand the vicious cycle: thrombosis → fibrinolysis → bleeding. Recognize precipitating conditions: DIC is not a primary disease.

Common Misconceptions

DIC is not synonymous with consumption coagulopathy—other conditions (massive transfusion, liver disease) cause similar laboratory abnormalities. Treatment is management of the underlying trigger, not anticoagulation or platelet transfusion in most cases.

Explainer

Disseminated intravascular coagulation is one of the most counterintuitive syndromes in medicine: the patient is simultaneously clotting everywhere and bleeding uncontrollably. To make sense of this, start with what you already know about hemostasis. Normal clot formation is tightly localized and regulated — tissue factor (TF) is exposed only at a wound site, thrombin generation is amplified locally, and natural anticoagulants like antithrombin and protein C keep the process contained. DIC is what happens when this localization fails completely.

The trigger is systemic tissue factor exposure. In sepsis, endotoxin and cytokines cause endothelial cells and monocytes to express TF throughout the vasculature. In trauma, massive tissue destruction releases TF directly into the circulation. Malignancies (particularly acute promyelocytic leukemia) shed procoagulant material continuously. Obstetric catastrophes like amniotic fluid embolism introduce TF into the pulmonary circulation. In each case, TF encounters circulating factor VII and ignites the extrinsic coagulation cascade — not at one wound site, but simultaneously across the entire vascular tree. Thrombin is generated in enormous quantities, converting fibrinogen to fibrin and activating platelets systemically. Fibrin strands deposit in small vessels throughout the body, causing microvascular thrombosis and the mechanical shearing of red blood cells (producing schistocytes on blood smear — a hallmark finding). Organ ischemia follows in the kidneys, lungs, liver, and brain.

Here is the paradox: the same thrombin that causes clotting also triggers consumption. Every platelet activated is one removed from the circulating pool. Every fibrinogen molecule converted to fibrin is one no longer available for the next clot. Antithrombin and protein C, the natural brakes on coagulation, become depleted trying to contain the runaway activation. Meanwhile, the massive fibrin deposition triggers a compensatory surge in fibrinolysis: plasmin is generated to break down clots, producing fibrin degradation products (particularly D-dimer, another diagnostic hallmark). By the time a patient presents clinically, platelet count is crashing, fibrinogen is depleted, PT and aPTT are prolonged (clotting factors exhausted), and D-dimer is elevated — a laboratory picture that directly reflects the thrombosis-then-consumption sequence.

The clinical paradox resolves when you follow the timeline. Early DIC manifests as thrombosis — microthrombi in capillaries, organ dysfunction. Late DIC manifests as bleeding — from IV sites, mucous membranes, surgical wounds — because the raw materials for clotting have been exhausted. Both are the same process at different stages. The treatment principle follows from the mechanism: address the trigger. The consumption will stop only when the source of TF exposure is controlled — the infection treated, the malignancy addressed, the obstetric complication resolved. Treating the coagulopathy in isolation (platelet transfusions, fresh frozen plasma) temporarily replenishes substrates but does nothing to stop the consumption. This is why understanding DIC as a secondary syndrome — always driven by an underlying cause — is not just academic but determines the entire therapeutic strategy.